[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"locally-advanced-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:locally-advanced-cancer":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,57],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100579768","early-phase-1-pilot-study-of-68gaga-aby-025-imaging-in-patients-undergoing-treatment-with-her2-targeted-therapy-100579768",false,"NCT06828588","Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients with unresectable locally advanced or metastatic cancer who are eligible for standard of care treatment with HER2-targeted therapy per the discretion of their treating physician for an FDA-approved indication. Patients who are planning to start HER2-targeted therapy at the time of study enrollment. Patients who have recently begun HER2 treatment and have received no more than 6 cycles will be eligible for enrollment.\n3. Must have a previous biopsy demonstrating HER2 expression in at least one lesion (HER2+ solid cancer, or breast cancer patients who are HER2+ or HER2-low) as defined by IHC and FISH studies or with HER2 amplification as defined by a liquid biopsy that was done as standard of care testing for the patient's cancer type.\n4. Measurable disease on CT, FDG-PET, or MRI imaging for RECIST evaluation; patient must have measurable disease outside the liver.\n5. Life expectancy of at least 6 months. Patients with brain metastases are permitted to enroll in this study.\n\nExclusion Criteria:\n\n1. Measurable sites of disease only in the liver.\n2. Inability to comply with study procedures.\n3. Hypersensitivity or allergy to any component of \\[68Ga\\]Ga-ABY-025.\n4. Pregnant or breastfeeding.\n5. HER2-negative cancers that have no FDA approved indication for treatment with HER2-directed therapy.\n6. Inability to lie flat for 30 minutes during an imaging session.\n7. Medical or psychiatric co-morbidities that, in the opinion of the treating physician, would prevent the patient from successfully participating in the study.","ALL","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"EARLY_PHASE1","The purpose of this study is to determine if the radiotracer, \\[68Ga\\]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.",[25,26,27,28,29],"Locally Advanced Cancer","Metastatic Cancer","HER2","HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma","HER 2 Low-expressing Breast Cancer",[27,31,32,33,34,35,36,37,38,39,40,41,42,43],"cancer","advanced cancer","metastatic","IHC","FISH","trastuzumab","T-DM1","Pertuzumab","Margetuximab","Neratinib","Lapatinib","Tucatinib","Everolimus","RECRUITING","2026-05-06",{"date":47,"type":48},"2026-05-08","ACTUAL",{"date":50,"type":48},"2026-04-16",{"date":52,"type":19},"2029-12",{"name":54,"class":55},"Vanderbilt-Ingram Cancer Center","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":65,"targetDuration":4,"studyType":20,"phases":67,"briefSummary":69,"conditions":70,"keywords":71,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100633640","evaluating-interventional-radiology-for-cancer-pain-management-100633640","NCT07529314","Evaluating Interventional Radiology for Cancer Pain Management","Evaluation of the Efficacy of Interventional Radiology in the Management of Pain in Patients With Cancer","RI-LieF","Inclusion Criteria:\n\n* Adult patient (age \\> 18 years);\n* Patient with locally advanced or metastatic cancer undergoing active management, including palliative care;\n* Patient with a clinically estimated life expectancy of at least 3 months;\n* Patient receiving treatment with chemotherapy, immunotherapy, targeted therapy, hormone therapy, or any other type of treatment for locally advanced or metastatic cancer;\n* Patient undergoing an interventional radiology procedure for pain relief (including cases where pain relief is not the primary objective);\n* Patient able to complete the proposed questionnaires.\n\nExclusion Criteria:\n\n* Patient with cancer in remission;\n* Patient with cured cancer;\n* Patient under routine follow-up.",{"count":66,"type":19},125,[68],"NA","Each year, the number of new cancer cases increases globally and the associated pain remains a major concern. The scientific literature shows that the prevalence and severity of cancer-related pain have decreased thanks to new therapeutic strategies and the efficacy of innovative treatments. Nevertheless, recent studies indicate that the prevalence of pain in patients with locally advanced or metastatic cancer remains high.\n\nCancer-related pain presents various characteristics, both in terms of timing (inflammatory and mechanical) and types (nociceptive, neuropathic, mixed, or visceral). This diversity in presentation and pathophysiology makes the condition complex, both in terms of symptom assessment and therapeutic management, requiring a multidisciplinary and often multimodal approach.\n\nIn addition to pharmacological approaches, several non-pharmacological techniques are used for this purpose, as the interventional radiology (IR), so-called minimally invasive technique. The role of IR is becoming increasingly important in pain management, particularly in the context of a growing number of cancer survivors, improved survival in the metastatic setting and the limited effectiveness of opioids. These techniques include neurolysis, embolization, consolidation techniques, ablation, and percutaneous cervical cordotomy.\n\nThe objective of the RI-Lief study is to evaluate the impact of interventional radiology on improving the quality of life of patients with locally advanced or metastatic cancer.\n\nAs part of the study, interventional radiology will be included in the standard patient care. The only additional procedure introduced by the research is the administration of questionnaires.",[25,26],[72,73],"Cancer","Pain","NOT_YET_RECRUITING","2026-04-13",{"date":77,"type":48},"2026-04-14",{"date":79,"type":19},"2026-09-01",{"date":81,"type":19},"2028-09-01",{"name":83,"class":55},"Hospices Civils de Lyon"]